Search results
Found 77 matches for
The company plans to develop Lilly’s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for the treatment of atherosclerotic cardiovascular disease and potentially other conditions.
PepGen announces appointment of two new directors to its Board
30 March 2025
The company announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors.
Moa named one of TIME's top greentech companies in 2025
26 March 2025
Moa recognised as leading global innovator in environmental impact.
Moa forms new biological partnership with NAICONS
25 March 2025
Oxford-based agricultural biotech firm Moa Technology has stepped up the global hunt for a safe, effective and affordable biological herbicide by forming a new partnership with NAICONS, an Italian natural products company.
OMass Therapeutics appoints Birgitte Volck as Non-Executive Director
26 February 2025
Oxford, United Kingdom – 26 February 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that Birgitte Volck MD, PhD has joined its Board as a non-executive director.
Enara Bio embarks on a research collaboration with George Washington University to deepen understanding of Dark Antigen® biology and expression
18 February 2025
Collaboration may inform future combination strategies that can maximise the efficacy of Enara Bio’s pipeline of TCR-based immunotherapies targeting Dark Antigens®
Enara Bio listed in the inaugural edition of The Sunday Times 100 Tech 2025
22 January 2025
The guide showcases Britain's fastest-growing private tech companies from The Sunday Times, commercialising innovation across the UK. "This recognition is a testament to our innovative science and the hard work of our incredible team as we strive to develop safe and effective treatments for cancer patients." Enara Bio
Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS
9 January 2025
The agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform.
Theolytics appoints David Apelian MD, PhD, MBA as CEO
17 December 2024
David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics. Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer.
OMass Therapeutics strengthens its leadership team with the promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-Clinical
6 December 2024
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that the Company has promoted Dr Hsin Loke to Chief Operating Officer (COO) and Jon Roffey Ph.D. to Senior Vice President, Discovery and Non-Clinical, effective immediately.
Theolytics doses first patient in Phase I/IIa Trial of THEO-260 in ovarian cancer
19 November 2024
Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC).
OMass Therapeutics appoints Professor Steven Charlton as Chief Scientific Officer
15 November 2024
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO), effective 1 December 2024. He will take on the role from Dr Ali Jazayeri, who is leaving OMass to pursue other opportunities.
CyanoCapture at the forefront: H2Boost deployment and COSEC Horizon grant to scale biogenic CO2 capture
10 November 2024
CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress toward a sustainable, low-carbon future.
Nucleome Therapeutics announces a strategic collaboration with Johnson & Johnson to map genetic associations linked to autoimmune disease
21 October 2024
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today it has entered a research collaboration with Johnson & Johnson*.
Internationally renowned academic Lee Sweetlove joins Moa
15 October 2024
Moa Technology is pleased to announce that Lee Sweetlove, Professor of Plant Sciences at the University of Oxford, has joined our team. Professor Sweetlove will be working to further understanding of the novel herbicidal modes of action discovered by Moa, which we are currently developing into safe, effective and affordable solutions to protect harvests from crop-killing weeds.
Moa’s groundbreaking science features in journal Weed Science
9 October 2024
Breaking the 30 year impasse in novel herbicide discovery.
Enara Bio raises $32.5M Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
2 October 2024
Enara Bio today announces the closing of a $32.5M Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors, including RA Capital, Samsara BioCapital and SV Health Investors.
OMass Therapeutics expands development team with key appointments in US and UK and announces the nomination of clinical candidate against MC2
30 September 2024
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the candidate nomination of its lead program targeting the melanocortin-2 (MC2) receptor and key appointments to support its progress towards becoming a clinical-stage company.
Moa and Biomar announce bio-herbicide collaboration
16 September 2024
Moa has boosted its bio-herbicide research and development programme with a new long-term collaboration agreement with Biomar Microbial Technologies.
Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer
11 September 2024
Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab’s Chief Scientific Officer (CSO), has succeeded Young Kwon, PhD as Chief Executive Officer (CEO) and member of the Board.
CardiaTec secures $6.5M seed funding to advance its multi-omics drug discovery platform for cardiovascular diseases
9 September 2024
CardiaTec, a TechBio company employing computational methods to decode the biology behind cardiovascular disease, has secured $6.5M in seed funding led by Montage Ventures with participation from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures.